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Neuropeptide B and neuropeptide W as new serum 
predictors of nutritional status and of clinical outcomes 
in pediatric patients with type 1 diabetes mellitus 
treated with the use of pens or insulin pumps
Teresa Grzelak1, Anna Wedrychowicz2, Joanna Grupinska3, Marta Pelczynska4, Marcelina Sperling4, 
Aniceta A. Mikulska4,5, Violetta Naughton6, Krystyna Czyzewska4
A b s t r a c t
Introduction: The aim of our study was to determine the relationship be-
tween neuropeptide B (NPB), neuropeptide W  (NPW), nutritional and anti-
oxidant status and selected fat- and bone-derived factors in type 1 diabe-
tes mellitus (T1DM) treated using pens (T1DM pen group) or insulin pumps 
(T1DM pump group) in order to investigate the potential role of NPB and 
NPW in the clinical outcomes of T1DM. 
Material and methods: Fifty-eight patients with T1DM and twenty-five 
healthy controls (CONTR) participated in the study. Assessments of NPB, NPW, 
total antioxidant status (TAS), leptin, adiponectin, osteocalcin, and free sol-
uble receptor activator for nuclear factor κB (free sRANKL) were conducted. 
Results: NPB, NPW, leptin, and TAS were lower (by 33%, p < 0.013; 34%, 
p < 0.008; 290%, p < 0.00004; 21%, p < 0.05; respectively), while adiponec-
tin was by 51% higher (p < 0.006) in T1DM vs. CONTR, while osteocalcin and 
free sRANKL levels were similar in both groups. NPW was lower in the T1DM 
pen group both vs. the T1DM pump group (36% lower, p < 0.0009) and vs. 
the CONTR group (35% lower, p < 0.002). In the T1DM pen group, but not in 
the T1DM pump group or the CONTR group, the Cole index and TAS levels 
explain (besides NPB) the variation in NPW values. ROC curves showed that 
serum levels of leptin, adiponectin, NPB and NPW (but not osteocalcin or 
free sRANKL) were predictive indicators for T1DM.
Conclusions: Measurements of NPB and NPW, besides leptin and adiponec-
tin, are worth considering in the detailed prognosis of nutritional status in 
T1DM, primarily in the T1DM pen-treated population. 
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Introduction
The etiopathogenesis of type 1 diabetes melli-
tus (T1DM) is not yet fully understood. The liter-
ature indicates the involvement of elements from 
the central nervous system (CNS) as well as adi-
pose and bone tissues in addition to autoimmune 
mechanisms [1, 2]. Of the CNS, neuropeptide B 
(NPB) and neuropeptide W (NPW) are suspected 
to play a role in etiopathogenesis and/or outcome 
of T1DM [3, 4]. Both neuropeptides demonstrate 
expression in pancreatic β cells [4]. Furthermore, 
published results from in vivo studies suggest that 
NPW exerts a potent suppressive effect on blood 
leptin concentrations, showing its direct involve-
ment in regulation of energy homeostasis [3, 4]. Of 
adipose tissue, certain adipokines, such as leptin 
and adiponectin, have been shown to play a role 
in the regulation of carbohydrate metabolism 
and via those mechanisms potentially contribute 
to the outcomes of T1DM [5, 6]. Leptin has been 
shown to affect insulin secretion via ATP-sen-
sitive potassium channels in pancreatic β cells 
through AMP-activated protein kinase (AMPL) 
and cAMP-dependent protein kinase (PK), as well 
as depolarization of F-actin [7]. It has also been 
demonstrated in an in vivo model of leptin recep-
tor knockout mice that the glucose-dependent in-
sulin secretion is partially normalized, though only 
in young female animals [8]. Furthermore, it has 
been previously shown that leptin has a  signifi-
cant effect on the stimulation of proinflammatory 
cytokines production in T1DM [9]. Adiponectin, on 
the other hand, is a protein that affects the central 
control of appetite, the regulation of the body’s 
energy, and glucose and lipid metabolism. This 
peptide has been previously shown to increase the 
activity of AMP-activated kinase (AMPK) through 
two independent pathways involving liver kinase 
B1 (LKB1) and Ca2+/calmodulin-dependent protein 
kinase (CaMKK), which via AMPK suppression of 
acetyl CoA carboxylase (ACC) have a lowering ef-
fect on malonyl-CoA production, thereby increas-
ing the oxidation of long chain fatty acids and cir-
cumventing insulin-mediated lipid synthesis [10]. 
Increased adiponectin levels have been reported 
in weight-loss-related diseases [11]. Moreover, 
published results indicate that adiponectin influ-
ences insulin sensitivity in T1DM [12]. Therefore it 
could be hypothesized that deregulation of the cir-
culatory level of both leptin and adiponectin could 
cause insulin resistance in patients with T1DM 
[8, 12]. Another mechanism that may be associ-
ated with etiopathogenesis (and/or outcomes) of 
T1DM concerns interactions between osteo-me-
tabolites and insulin. It is acknowledged that in-
sulin promotes osteocalcin activation in the feed-
back loop, which in turn drives the synthesis and 
secretion of insulin [13], while the remodeling of 
the skeleton closely depends on insulin, amongst 
other endocrine factors, including those secreted 
by adipocytes discussed above. To elaborate, it 
has been shown that osteocalcin stimulates insu-
lin release and proliferation of pancreatic β cells in 
laboratory animals, with a  concomitant increase 
of peripheral blood glucose uptake, as well as an 
increase of the breakdown of adipose tissue [14]. 
On the other hand, it has been observed that the 
level of osteocalcin in the blood is decreased in 
starvation [15], while intraperitoneal administra-
tion of osteocalcin in vivo increases energy expen-
diture, improves glucose tolerance, and regulates 
insulin sensitivity without affecting the activity of 
the animals [16]. Moreover, rodents with a deac-
tivated gene for osteocalcin are characterized by 
a  carbohydrate metabolism disorder, while sim-
ilar health problems have been reported in men 
who carry heterozygous mutations in the trans-
membrane domain of the osteocalcin receptor 
(GPRC6A) [17]. Furthermore, soluble receptor acti-
vator for nuclear factor-κB ligand (sRANKL), which 
has mainly been studied in relation to bone me-
tabolism balance [18] has been recently indicated 
in pathogenesis of T1DM [19, 20]. Additionally, it 
has been shown in in vivo models that turning off 
the gene encoding RANKL impairs T lymphocyte 
differentiation, which could potentially be related 
to pathogenesis of T1DM. Recent blood concen-
tration studies of the total soluble RANKL pool 
have shown that it is a  predictor of ossification 
disorders in T1DM pediatric and adult patients 
[21]. To our knowledge, however, there are no 
published data on the association between the 
free form of sRANKL with carbohydrate balance in 
patients with this disease. 
Another mechanism that has been implicated 
in pathogenesis of T1DM relates to previously re-
ported disorders of oxidative-reduction balance 
[22]. It has been shown in vitro that oxidative 
stress leads to a  change in activity of the ade-
nosine-5’-triphosphate channel, and thus of the 
function of pancreatic β cells [23]. However, the 
oxidative-reduction balance has not been fully 
explored yet in T1DM pediatric patients, although 
total antioxidant status (TAS) has been previous-
ly proposed as a prognostic tool in patients with 
T1DM [22, 23].
Collectively, the literature indicates that the 
CNS, as well as adipose and bone tissue may play 
a  role in the etiopathogenesis and/or outcomes 
of T1DM. Moreover, the above-presented results 
from in vitro studies and in vivo models indicate 
the specific peptides/proteins, i.e. NPB, NPW, 
leptin, adiponectin, osteocalcin, free sRANKL, and 
TAS, that collectively could serve as biomarkers of 
T1DM progression. However, to the best of our 
knowledge, there are no clinical results available 
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on the above-listed peptides/proteins and other 
factors in pediatric patients presenting T1DM. 
Therefore the aim of this study was to assess the 
levels NPB, NPW, leptin, adiponectin, osteocalcin, 
free sRANKL, and TAS in pediatric patients pre-
senting T1DM and to evaluate the relationship 
between assessed levels of NPB, NPW in serum, 
nutritional and antioxidant status indices, and 
other listed factors from adipose and/or bone tis-
sue in pediatric patients with T1DM. Additionally, 
we investigated the effects of two different types 
of insulin administration, i.e. either via insulin 
pens, or continuous subcutaneous insulin infusion 
devices, to assess whether pulsatile or continuous 
insulin supply reflects any changes to investigated 
regulatory pathways from the CNS, adipose tissue 
and bone. We hypothesize that pediatric T1DM 
patients will show altered serum levels of NPB 
and NPW, leptin, adiponectin, osteocalcin, free 
sRANKL, and TAS and that those parameters will 
exhibit associations indicative of the interplay be-
tween the CNS, adipose and bone-derived mecha-
nisms in T1DM. Furthermore, we hypothesize that 
the potential relationships between the levels of 
these parameters might be affected by the degree 
of glycemic control (inter alia connected with the 
method of insulin administration, i.e. pulsatile or 
continuous), and thus indicative of the effects of 
insulin delivery on the investigated crosstalk be-
tween neuropeptides, bone-derived molecules 
and adipokines.
Material and methods
This study was approved by the Local Bioethics 
Committee (KBET/128/B/2010, 1072.6120.25.2018) 
and was conducted in accordance with the WMA 
Declaration of Helsinki [24]. Written informed con-
sent regarding participation/the right to withdraw 
from participation in the study was obtained from 
all study participants and/or their legal represen-
tatives prior to the study commencement.
Subjects
A  group of 58 Caucasian subjects (age range 
4–17 years), previously diagnosed (3.4 ±2.6 years) 
with T1DM, were included in the diabetic patient 
group (T1DM group). Additionally, 25 age-, gen-
der- and puberty-matched healthy subjects were 
recruited as healthy controls (CONTR group). 
There were no differences regarding pubertal sta-
tus (according to the Tanner scale) between T1DM 
and CONTR groups [25]. A total of 47 females and 
36 males were examined. The diabetic patients 
(T1DM group) were treated with functional insulin 
therapy, either with human insulin (n = 16) or in-
sulin analogs (n = 42), while the medications were 
administered via either insulin pens (n = 31) or 
continuous subcutaneous insulin infusion devices 
(insulin pumps; n = 27). None of the healthy sub-
jects studied had any history of clinical or laborato-
ry (e.g., fasting blood glucose, urea, and electrolytes, 
liver, and thyroid function tests) signs of diseases 
associated with dysfunction of the endocrine pan-
creas and were taking no prescribed medication. 
Anthropometric measures  
and blood sampling 
Anthropometric evaluation of each subject 
was carried between 7:30 and 8:30 and after an 
overnight rest and fasting (for a minimum of 12 h) 
and included: weight (kg; in light underwear and 
unshod, using a certified scale of 0.1 kg accura-
cy) and height (cm; using a stadiometer of 0.1 cm 
accuracy). Obtained data were further used to cal-
culate a standard deviation score (SDS) for height, 
body mass index (BMI), BMI z-score, Cole index, 
and BMI-for-age percentile, with reference to the 
Polish charts for height, body weight, and BMI 
[26]. The anthropometric data are presented in 
Table I. Following the anthropometric evaluation, 
5 ml of venous blood was collected from the elbow 
vein from each individual. One milliliter of fresh 
blood collected from the diabetic patients (T1DM 
group) was immediately analyzed for glycated he-
moglobin (HbA1c). The remaining blood from the 
T1DM group, as well as the blood samples from 
the healthy subjects, were allowed to clot (at room 
temperature, 30  min) prior to centrifugation at 
350 × g, and the obtained serum samples were 
stored at –80°C for further biochemical analyses. 
Serum concentrations of the biomarkers list-
ed below were determined using validated en-
zyme-linked immunosorbent assays, according to 
the manufacturers’ guidelines: Leptin, DiaSource 
ImmunoAssays (Louvain-la-Neuve, Belgium), in-
tra- and interassay coefficients of variation (CVs) 
4.1%, and 5.0%, respectively; adiponectin, Dia-
Source ImmunoAssays (Louvain-la-Neuve, Bel-
gium), intra- and interassay CVs 2.9% and 3.8%, 
respectively; osteocalcin, DiaSource ImmunoAs-
says (Louvain-la-Neuve, Belgium), intra- and in-
terassay CVs 4.2% and 5.7%, respectively; free 
sRANKL, Biomedica Medizinprodukte (Vienna, 
Austria), intra- and interassay CVs 3.1% and 3.8%, 
respectively; NPB, Shanghai Sunredbio (SRB) 
Technology Co., Ltd. (Shanghai, China), intra- 
and interassay CVs 4.9% and 5.5%, respectively; 
NPW (Shanghai Sunredbio (SRB) Technology Co., 
Ltd, Shanghai, China), intra- and interassay CVs 
4.2% and 6.0%, respectively. Threshold values 
for leptin, adiponectin, osteocalcin, free sRANKL, 
NPW and NPB analyses were lower than or equal 
to 0.1 ng/ml, 0.09 ng/ml, 0.08 ng/ml, 0.16 pg/ml, 
2.5 pg/ml and 5.0 pg/ml, respectively, in undilut-
ed samples.
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HbA1c level was determined by high-perfor-
mance liquid chromatography (HPLC) using a Bio-
Rad unit equipped with BioMatrix Clinical Data 
Management for data archiving. This assay al-
lowed for the analysis of the stable HbA1c form 
without interference with hemoglobin F, carbon-
ylated hemoglobin, or labile HbA1c [27]; the refer-
ence range for HbA1c was 4.6–6.3%. 
The serum TAS, as a parameter of extracellular 
protection against pro-oxidant activity, was de-
termined by Randox Total Antioxidant Status kits 
(Crumlin, UK). TAS analysis was based on the incu-
bation of a patented molecule, 2,2-azino-di-(3-eth-
ylbenzthiazoline sulfonate) (ABTS), with perox-
idase (metmyoglobin) and hydrogen peroxide, 
which produced a radical cation ABTS+ with char-
acteristic color (wavelength detection at 600 nm). 
Thresholds for TAS analyses in undiluted samples 
were set between 0.21 and 2.94 mmol/l [28].
Statistical analysis
The results were analyzed statistically, using 
elements of descriptive statistics and statistical 
procedures of correlation analysis of the vari-
ables (with the Spearman and Pearson tests), 
analysis for comparing medians for unrelated 
data (Mann-Whitney U  test, Student’s t-test or 
Welch’s ANOVA test, post-hoc test – Dunn test 
for nonparametric data) and receiver operating 
characteristic (ROC) comparison of the areas un-
der curves. Statistical analysis of the results was 
conducted using Statistica 12.5 (StatSoft, USA). 
The results are presented as mean ± standard 
deviations and medians (with upper and lower 
quartiles). The normality of the data distribution 
of small groups (less than 50 people) was as-
sessed using the Shapiro-Wilk test, and for large 
groups using the Kolmogorov-Smirnov test. Anal-
ysis of the homogeneity of variance was carried 
out using the Levene test. The level of statistical 
significance was taken as p < 0.05. In the multiple 
testing, Bonferroni correction was used. 
Results 
Anthropometric and biochemical characteris-
tics of individuals with T1DM and the control sub-
Table I. Anthropometric and biochemical characteristics of individuals with type 1 diabetes mellitus (T1DM) and 
matched, control healthy subjects (CONTR)
Parameter [unit] T1DM (n = 58) CONTR (n = 25) P-value
Sex 33 females/25 males 14 females/11 males NS
Age [years] 11.9 ±4.5; 12.0 (9.0; 16.0) 11.0 ±4.1; 12.0 (8.0; 15.0) NS
Height [m] 1.45 ±0.23; 1.51 (1.28; 1.63) 1.48 ±0.20; 1.49 (1.36; 1.65) NS
SDS of height –0.30 ±1.10; –0.30 (–0.88; 0.33) 0.91 ±2.83; 0.30 (–0.18; 1.33) < 0.02
Body mass [kg] 42.6 ±19.3; 42.3 (26.0; 55.6) 54.8 ±26.9; 53.0 (41.0; 57.1) < 0.05
Cole index 102.99 ±16.67; 101.54 (94.22; 111.28) 132.47 ±38.25; 126.56 (99.18; 169.20) < 0.003
BMI [kg/m2] 18.96 ±4.21; 17.95 (15.82; 21.44) 23.73 ±7.68; 21.62 (18.65; 27.78) < 0.004
BMI z-score –0.12 ±1.19; 0.03 (–0.73; 0.68) 1.05 ±1.64; 1.61 (–0.22; 2.31) < 0.0009
Body mass index-for-
age percentile
49.38 ±29.56; 51.50 (23.25; 74.75) 72.28 ±33.80; 95.00 (41.00; 99.00) < 0.0008
Total antioxidant 
status [mmol/l]
1.20 ±0.31; 1.21 (1.02; 1.46) 1.45 ±0.23; 1.51 (1.15; 1.62) < 0.004
Leptin [ng/ml] 2.10 ±2.98; 0.95 (0.32; 2.52) 6.09 ±5.53; 3.68 (2.07; 8.03) < 0.00004
Adiponectin [μg/ml] 10.88 ±5.49; 10.37 (6.90; 13.35) 7.18 ±5.26; 5.00 (4.10; 10.20) < 0.006
Osteocalcin [ng/ml] 29.83 ±18.14; 27.32 (15.89; 39.81) 27.42 ±16.63; 24.32 (13.15; 37.70) NS
Free sRANKL [pg/ml] 3.04 ±4.50; 1.60 (0.20; 3.94) 3.26 ±3.50; 2.60 (0.20; 4.00) NS
HbA1c [%] 7.99 ±1.67; 7.60 (6.90; 8.80) – –
Neuropeptide B [ng/ml] 0.28 ±0.19; 0.21 (0.19; 0.26) 0.34 ±0.18; 0.28 (0.24; 0.41) < 0.013
Neuropeptide W [ng/ml] 0.36 ±0.25; 0.27 (0.22 ;0.35) 0.44 ±0.23; 0.36 (0.27; 0.50) < 0.009
Parameters are shown as means ± standard deviations and medians (25% and 75% quartiles); T1DM – type 1 diabetes mellitus, CONTR – 
control group, n – number of individuals studied, p – level of statistical significance in Mann-Whitney test for nonparametric data or t-test 
for parametric data (possibly Welch’s ANOVA test for variance or c2 test for qualitative data), SDS of height – standard deviation score of 
height, BMI – body mass index, BMI z-score – body mass index z-score, free sRANKL – free soluble receptor activator of nuclear factor-κB 
ligand, HbA
1c
 [%] – % of glycated hemoglobin A
1c
, NS – difference not statistically significant.
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jects (CONTR) are shown in Table I. The T1DM pa-
tients had lower body mass (25% lower; p < 0.05), 
BMI (25% lower; p < 0.004) and TAS (21% lower; 
p < 0.004) as compared with the CONTR group (Ta-
ble I). In addition, the patients had higher levels of 
adiponectin (51% higher; p < 0.006). However, no 
differences (p > 0.05) were noted in serum osteo-
calcin and free sRANKL between T1DM patients 
and control subjects. The concentrations of NPB 
and NPW in the T1DM group were lower (33%, 
p < 0.013 and 34%, p < 0.008, respectively), than 
in the CONTR group (Table I).
A positive correlation was found between NPB 
and leptin concentrations in the whole popu-
lation (R = 0.27, n = 83, p < 0.016, Figure 1 A). 
Similarly, positive correlations were found be-
tween NPB and NPW levels in this group 
(R = 0.69, n = 83, p < 0.000001) and in the T1DM 
patients (R = 0.64, n = 58, p < 0.000001). Further-
more, a significant positive correlation was found 
between levels of NPB and NPW in both sub-
groups of T1DM patients treated using insulin 
pens (R = 0.45; p < 0.02), and the insulin pumps 
(R = 0.79; p < 0.000001). A  positive correlation 
was found between NPB and NPW in both gen-
der groups, i.e. in the total female population (R = 
0.71; p < 0.000001) and the total male population 
(R = 0.62; p < 0.000001). Furthermore, the male 
group showed a positive correlation between NPB 
and leptin (R = 0.33; p < 0.05, Figure 1 B).
In males with T1DM assessed levels of leptin 
and the BMI z-score were lower (p < 0.0008 and 
p < 0.018, respectively) and osteocalcin concen-
trations were higher (p < 0.018) than among 
the females with T1DM. The median (25%; 75% 
quartiles) HbA1c was 7.65% (6.90; 8.80%) in the 
T1DM group and level of this parameter (and also 
BMI z-score and leptin) showed 21% lower values 
in males with T1DM than in females with T1DM 
(Table II).
In the T1DM group there was a  positive cor-
relation between osteocalcin and height (R = 0.37; 
p < 0.005), osteocalcin and body mass (R = 0.29; 
p < 0.03), osteocalcin and the Cole index (R = 
0.27; p < 0.001), osteocalcin and BMI (R = 0.39; 
p < 0.002), osteocalcin and BMI z-score (R = 0.27; 
p < 0.05), osteocalcin and BMI-for-age percentile 
(R = 0.27; p < 0.04) and finally, a negative correla-
tion between osteocalcin and leptin levels (R = 
–0.50; p < 0.0008, Table III).
The T1DM pen group had 36% lower concen-
tration of NPW (p < 0.0009) than the T1DM pump 
group and the T1DM pen group had 6% high-
er level HbA1c (p < 0.006) than the T1DM pump. 
Compared with the CONTR group, the T1DM pen 
group had a 35% lower level of NPW (p < 0.002) 
and 29% lower level of NPB (p < 0.024). Anthropo-
metric parameters were found to be affected by 
the mode of insulin delivery, i.e. the patients treat-
ed with the insulin pens had 41% lower BMI-for-
age percentile (p < 0.012), 25% lower Cole index 
(p < 0.025) as well as a decreased leptin concen-
tration (by 81%; p < 0.00009) but a 91% higher 
level of serum adiponectin (p < 0.03). The T1DM 
pump group had 45% lower body mass index-for-
age percentile (p < 0.006), 58% lower leptin con-
centration (p < 0.006) but a 110% higher level of 
adiponectin (p < 0.012) in comparison with the 
CONTR group (Table IV). A positive correlation was 
found in the T1DM pen group (n = 31) between 
NPW and TAS (R = 0.33; p < 0.033, Figure 2). 
The multivariable model showed a significant 
effect of Cole index and TAS on the variability 
of serum values of NPW in the T1DM pen group 
(p < 0.003, R2adj (adjusted R2) = 32%) (Table V). 
To describe this phenomenon more precisely, an 
additional variable was included in the model, 
namely, values of serum concentration of NPB. 
Adding NPB value to the multivariable model 
allowed a better explanation of the variation in 
NPW: up to 86% (p < 0.0000001). In the case of 
the second group (T1DM pen users) the multi-
variable model showed a lack effect of Cole index 
and TAS on the variability of NPW (Table V). In the 
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Table II. Anthropometric and biochemical characteristics of patients with type 1 diabetes mellitus (T1DM) by sex
Parameter [unit] Females (n = 31) Males (n = 27) P-value
Age [years] 12.0 ±4.0; 13.0 (9.0; 16.0) 11.0 ±4.9; 12.0 (7.0; 15.0) NS
Height [m] 1.49 ±0.19; 1.58 (1.41; 1.63) 1.40 ±0.26; 1.49 (1.14; 1.63) NS
SDS of height –0.17 ±2.05; –0.28 (–0.90; 0.26) –0.52 ±1.61; –0.52 (–4.00; 1.50) NS
Body mass [kg] 46.6 ±19.5; 47.0 (29,5; 61.0) 38.1 ±18.3; 38.7 (18.5; 52.7) NS
Cole index 113.27 ±28.43; 104.51 (94.70; 130.30) 99.56 ±11.86; 101.04 (70.85; 122.26) NS
BMI [kg/m2] 20.86 ±6.23; 19.49 (16.18; 24.56) 17.94 ±3.01; 17.60 (13.46; 23.78) NS
BMI z-score 0.03 ±1.33; 0.26 (–0.73; 0.99) –0.28 ±1.01; –0.13 (–0.72; 0.33) < 0.018
Body mass index- 
for-age percentile
54.19 ±31.19; 60.00 (23.50; 84.00) 43.85 ±27.08; 45.00 (23.50; 63.00) NS
Total antioxidant 
status [mmol/l]
1.17 ±0.40; 1.18 (0.95; 1.34) 1.23 ±0.26; 1.31 (1.13; 1.40) NS
Leptin [ng/ml] 3.28 ±3.65; 1.77 (0.69; 4.28) 0.75 ±0.73; 0.44 (0.18; 1.10) < 0.0005
Adiponectin [μg/ml] 11.82 ±5.19; 11.52 (8.15; 13.73) 9.80 ±5.72; 8.30 (6.42; 12.52) NS
Osteocalcin [ng/ml] 25.00 ±16.89; 24.17 (10.40; 33.12) 35.37 ±18.23; 34.10 (23.69; 42.19) < 0.017
Free sRANKL [pg/ml] 3.10 ±5.20; 1.40 (0.20; 3.90) 2.96 ±3.68; 1.80 (0.40; 3.90) NS
HbA1c [%] 8.04 ±1.67; 7.65 (6.00; 13.30) 7.91 ±1.78; 6.30 (6.10; 9.30) < 0.049
Neuropeptide B [ng/ml] 0.30 ±0.22; 0.22 (0.19; 0.29) 0.26 ±0.17; 0.21 (0.19; 0.24) NS
Neuropeptide W [ng/ml] 0.38 ±0.26; 0.28 (0.23; 0.41) 0.33 ±0.23; 0.25 (0.22; 0.32) NS
Parameters are shown as means ± standard deviations and medians (25% and 75% quartiles); T1DM – type 1 diabetes mellitus, n – 
number of individuals studied, p – level of statistical significance in Mann-Whitney test for nonparametric distributions or t-test for 
parametric data (possibly Welch’s ANOVA test for variance), SDS of height – standard deviation score of height, BMI – body mass index, 
BMI z-score – body mass index z-score, free sRANKL – free soluble receptor activator of nuclear factor-κB ligand, HbA
1c
 [%] – % of glycated 
hemoglobin A
1c
 [%], NS – difference not statistically significant.
Table III. Indices of correlation and levels of statistical significance between leptin and anthropometric, biochemi-
cal and antioxidant parameters in the type 1 diabetes mellitus (T1DM) group (n = 58), T1DM group treated using 
insulin pens (T1DM pen group, n = 31) and T1DM group treated using insulin pumps (T1DM pump group, n = 27)
Parameter [unit] Leptin in T1DM Leptin in T1DM pen group Leptin in T1DM pump group 
R P-value R P-value R P-value
Body mass [kg] 0.59 < 0.00001 0.86 < 0.0000001 0.72 < 0.00003
Height [m] 0.42 < 0.001 0.67 < 0.00004 0.62 < 0.0006
SDS of height – NS – NS – NS
Cole index 0.56 < 0.0001 0.68 < 0.00003 0.52 < 0.006
BMI [kg/m2] 0.67 < 0.0000001 0.88 < 0.0000001 0.39 < 0.05
BMI z-score 0.62 < 0.0000001 0.59 < 0.0006 0.60 < 0.001
Body mass index-for-age 
percentile
0.62 < 0.0000001 0.59 < 0.0005 0.60 < 0.0009
Total antioxidant status 
[mmol/l]
– NS – NS – NS
Free sRANKL [pg/ml] – NS – NS – NS
Adiponectin [μg/ml] – NS – NS – NS
Osteocalcin [ng/ml] –0.50 < 0.0008 –0.59 < 0.0006 –0.49 < 0.01
HbA1c [%] – NS – NS – NS
Neuropeptide B [ng/ml] – NS – NS – NS
Neuropeptide W [ng/ml] – NS – NS – NS
R – coefficient of Pearson or Spearman (for respectively parametric or non-parametric date distributions), p – level of statistical significance, 
free sRANKL – free soluble activator of nuclear factor-κB ligand, HbA
1c 
[%] – % of glycated hemoglobin A
1c
, NS – difference not statistically 
significant.
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last group, only levels of NPB (from investigated 
parameters) explain the variation in serum val-
ues of NPW, similar as in the case of the CONTR 
group. A positive correlation was found between 
TAS and leptin levels (R = 0.41; p < 0.039) in the 
CONTR group, but there was no significant rela-
tionship in the T1DM group. 
Comparative analysis of ROC curves (graphical 
characteristics) showed that area under the curve 
(AUC) levels of NPB, NPW and adiponectin were 
Table IV. Anthropometric and biochemical characteristics of individuals with type 1 diabetes mellitus (T1DM) 
treated using insulin pens (T1DM pen group, n = 31) or insulin pumps (T1DM pump group, n = 27) and control 
groups (CONTR, n = 25)
Parameter [unit] T1DM pen group (n = 31) T1DM pump group (n = 27) CONTR (n = 25) P-value
Sex 16 females/15 males 12 females/15 males 14 females/11 males NS*; NS**
NS***


















































































































































Parameters are shown as means ± standard deviations and medians (25% and 75% quartiles); T1DM – type 1 diabetes mellitus, CONTR 
– control group; n – number of individuals studied, p – level of statistical significance in post-hoc test (Dunn test for nonparametric 
data) after Bonferroni correction, SDS of height – standard deviation score of height, BMI – body mass index, BMI z-score – body mass 
index z-score, TAS – total antioxidant status, free sRANKL – free soluble receptor activator of nuclear factor-κB ligand, HbA
1c
 [%] – 
% of glycated hemoglobin A
1c
, *level of statistical significance upon comparison of T1DM group using pens vs. T1DM group using pumps, 
**level of statistical significance upon comparison of T1DM group using pens vs. control (CONTR), ***level of statistical significance upon 
comparison of T1DM group using pumps vs. control (CONTR), NS – difference not statistically significant.
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comparable (the differences were not statistical-
ly significant) for AUC level in the case of leptin 
for pairs of studied groups (T1DM vs. CONTR) (for 
details, see Table VI, Figures 3, 4). The highest AUC 
values of ROC were found in the case of adiponec-
tin, and values were slightly lower in the cases of 
both NPW and NPB. Low sensitivity and specificity 
characterized osteocalcin and free sRANKL. More-
over, higher AUC level in the case of leptin in com-
parison for this parameter in the case of osteocal-
cin (p < 0.0003) and higher AUC level in the case of 
leptin in comparison to AUC level in the case of free 
sRANKL (p < 0.003, Figure 3) were demonstrated.
Discussion
Our results confirm the hypothesis that T1DM 
pediatric patients show altered serum levels of 
NPB and NPW, leptin, adiponectin, and TAS (but 
not in the case of osteocalcin and free sRANKL). 
Furthermore, we rejected the hypothesis stating 
that the relationships between the levels of stud-
ied parameters (except NPW) might be associated 
with the degree of glycemic control (and indirectly, 
with the method of insulin administration). This 
Figure 2. Correlation between serum levels of neu-
ropeptide W and total antioxidant status (TAS) in 
the type 1 diabetes mellitus treated using of insu-
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Table V. Comparison of the two models explaining variations of neuropeptide W in group of type 1 diabetes mel-
litus treated using insulin pens (T1DM pen group), group of type 1 diabetes mellitus treated using insulin pumps 
(T1DM pump group) and control group (CONTR) before and after adding the third variable (serum level of neuro-
peptide B) in the basic model, which includes Cole index and TAS
Dependent variable Statistical 
parameters
Model including 2 variables:  
Cole index and TAS [mmol/l]
Extended model with a new variable 
(level of neuropeptide B [ng/ml])
Neuropeptide W 




P-value 0.68 < 0.001
Neuropeptide W 
[ng/ml] in T1DM 




P-value < 0.003 < 0.0000001
Neuropeptide W  
[ng/ml] in T1DM 




P-value 0.83 < 0.0000001
TAS – total antioxidant status, n – number of individuals studied, R2adj – adjusted R-squared, p – level of statistical significance.
Table VI. Characteristics of ROC curves for serum concentrations of leptin, adiponectin, osteocalcin, free sRANKL, 
neuropeptide B, neuropeptide W for pairs of studied groups (T1DM vs. CONTR)
Parameter [unit] Cut-off value AUC SD (AUC) 95% CI P-value
Leptin [ng/ml] 1.07 0.81 0.05 0.72–0.90 0.000001
Adiponectin [μg/ml] 6.30 0.74 0.07 0.60–0.87 0.0005
Osteocalcin [ng/ml] 26.79 0.54 0.07 0.40–0.67 0.5661
Free sRANKL [pg/ml] 2.20 0.54 0.07 0.40–0.68 0.5748
Neuropeptide B [ng/ml] 1.00 0.67 0.07 0.54–0.80 0.0119
Neuropeptide W [ng/ml] 1.03 0.69 0.06 0.57–0.80 0.0015
Cut-off value – cut-off point on ROC (receiver operating characteristic) curve, AUC – area under receiver operating characteristic curve, 
SD (AUC) – standard deviation of AUC, p – level of statistical significance, free sRANKL – free soluble receptor activator of nuclear factor-κB 
ligand. 
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study was the first to show the levels of circulat-
ing NPB and NPW in pediatric patients suffering 
from T1DM. Our results showed significantly low-
er levels of both NPB and NPW in the diabetic pa-
tients as compared to non-diabetic healthy sub-
jects. To the best of our knowledge, there are no 
published results on the level of NPB and/or NPW 
in T1DM. However, previously published results 
from in vivo studies indicate a  clear association 
between those peptides and glucose metabolism. 
Namely, Rucinski et al. in a rat model showed that 
subcutaneous injections of NPB can affect both 
glucose (increase) and insulin levels (decrease) 
[4]. Furthermore, the possible mechanism of such 
regulation has been previously reported, as it has 
been shown that NPW causes a local increase in 
insulin secretion via increased Ca2+ ion in the cy-
tosol of pancreatic β cells [29]. Therefore, it could 
be suggested that our clinical results are in agree-
ment with the results from in vitro and in vivo 
models and thus indicate that both neuropeptides 
play a role in carbohydrate metabolism, including 
changes observed in T1DM.
In this study, patients presenting T1DM showed 
reduced serum NPB and NPW levels concomitant-
ly to lower body mass, lower values of Cole index, 
BMI, BMI z-score, and BMI-for-age percentile, and 
lower SDS of height compared to healthy peers. 
To the best of our knowledge, there are no pub-
lished results on the associations between NPB/
NPW and anthropometric parameters in T1DM pa-
tients, and the only results available on appetite/
food intake and nutritional parameters are report-
ed from in vivo experiments [30–33]. Experimen-
tal studies in rodents have shown that intragastric 
administration of protein stimulated an increase 
in NPW mRNA expression in the gastric muscles 
of female mice [34]. Moreover, it has been shown 
that long-term feeding with a high-fat diet did not 
alter the level of NPW expression, but short-term 
starvation did significantly decrease NPW expres-
sion in female mice, suggesting modifications de-
pendent on stimulation of the center of hunger 
and satiety [35]. In a  light of the findings from 
in vivo experiments it could be thus suggest-
ed that our findings on concomitant changes to 
NPB and NPW and anthropometric parameters 
in T1DM patients, albeit not direct, indicate the 
involvement of both peptides in carbohydrate me-
tabolism in diabetic patients. 
The results of our study showed a positive re-
lationship between serum concentrations of NPB 
Figure 4. Pareto chart of t-value coefficient for neuropeptide W (model including 3 variables: neuropeptide B, Cole 
index and TAS – Total Antioxidant Status) in group of type 1 diabetes mellitus treated using pens (T1DM pen group, A)  
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Figure 3. Receiver Operating Characteristic curves for 
serum levels of leptin, adiponectin, osteocalcin, free 
soluble receptor activator of nuclear factor-κB ligand 
(free sRANKL), neuropeptide B and neuropeptide W 
for the differentiation between patients with type 1 
diabetes mellitus (T1DM) and control group (CONTR)
Variable: neuropeptide W [ng/ml] in T1DM pens
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and leptin, although only in the male subjects. 
The lack of such a  relationship in the females 
could possibly indicate a  role of endocrine reg-
ulatory mechanisms. It has been reported that 
NPW-knockout female and male rodents show 
normal food intake [36], but only male NPB-knock-
out rodents develop adult obesity [37]. Hence the 
positive correlation between leptin and NPB in the 
males but not in females in this study could in-
dicate that NPB has a  greater involvement than 
NPW in regulating nutritional status in males, con-
necting with leptin-mediated pathways. 
The present study demonstrated no correla-
tion between concentrations of free sRANKL and 
anthropometric and biochemical parameters in 
all analyzed groups. According to the “free hor-
mones” hypothesis, only molecules not bound to 
plasma protein are free to migrate through cell 
membranes and to have metabolic effects, so the 
concentrations of free sRANKL that are unbound 
with osteoprotegerin seem to be independent of 
the level of plasma transport proteins. Loureiro 
et al. reported blood levels of total sRANKL frac-
tion (total free and osteoprotegerin bound-sol-
uble pool) in patients with T1DM comparable to 
those observed in healthy controls, but the s-os-
teoprotegerin (soluble form of its antagonist) was 
decreased in T1DM, stimulating increased bone 
resorption. Moreover, it has been reported that 
RANKL gene expression in peripheral blood leuko-
cytes was comparable in children and adolescents 
with well-controlled and poorly controlled T1DM 
(according to HbA1c) and the control group [38]. 
On the other hand, the systematic review by Sta-
rup-Linde showed the correlation of the total solu-
ble pool of RANKL in the blood with carbohydrate 
disorders (suppression of secretion in hyperglyce-
mia and a correlation between the concentrations 
of RANKL and leptin, adiponectin, antioxidant sta-
tus and concentration of insulin-like growth factor 1 
in patients with T1DM) [20]. However, results on 
the relations between serum concentrations of 
free sRANKL and the endocrine activity of adipose 
tissue or nutritional status in patients with this 
disease are not available. 
This study demonstrated a  larger total adi-
ponectin pool in patients with T1DM, as compared 
with healthy peers. This finding is in agreement 
with previously published results (Galler et al. [39], 
Al Saeed et al. [40], and Frystyk et al. [41]). More-
over, the concentrations of the adipokine observed 
in this study were negatively correlated with the 
level of osteocalcin. Kanazawa et al. have previ-
ously reported negative correlations of osteocal-
cin concentration in the blood of men with type 2 
diabetes with both visceral fat and subcutane-
ous fat as well as with fasting glucose levels [42]. 
Loureiro et al. found only negative correlations be-
tween serum osteocalcin and glucose as well as 
serum osteocalcin and % glycated hemoglobin A
1c 
in patients with abnormal glycemic control [38]. 
In this study (with the median of HbA1c: 7.65%), 
the differences between groups in serum osteo-
calcin concentrations were negligible, which could 
indicate that this phenomenon is predominantly 
associated with metabolically decompensated di-
abetes. It is worth noting that a negative correla-
tion between the concentration of this molecule 
and leptin was observed in this study. Published 
results on such relationships are currently not 
available in patients with T1DM, but Kanazawa 
et al. observed a  significant correlation between 
serum osteocalcin and index of visceral adiposity 
content in male patients with type 2 diabetes [42]. 
This would therefore suggest that both bone- and 
fat-derived molecules play important roles in an-
thropometric status in patients with T1DM. 
The reduction in the antioxidant status ob-
served in the patients with T1DM in this study in-
dicates a predominance of pro-oxidant processes 
over antioxidant processes. Similar results were 
observed in studies conducted in 2014 in patients 
with T1DM (with 31% lower values of TAS) and 
their siblings (26% lower values of TAS), compared 
to healthy peers without a history of this disease 
in the family [43]. Published results and the find-
ings of this study indicate the importance of ge-
netic pathomechanisms of lower antioxidant lev-
els in individuals predisposed to T1DM and thus 
may suggest that oxidative stress contributes to 
disease etiopathogenesis and its outcomes. Nota-
bly, no correlation between TAS level and duration 
of the disease and HbA1c [%] were demonstrated 
in this study and the previous results of Salmono-
wicz et al. [43]. The positive relationship between 
TAS and NPW in the T1DM pen group suggests an 
influence of this neuropeptide on the antioxidant 
system and/or vice versa. 
This study showed a  significant correlation 
between antioxidant status and leptin but only 
in control healthy subjects. This result suggests 
a  modification in the level of the index repre-
senting the ratio of pro-oxidant levels to anti-
oxidants, with carbohydrate balance disorders 
being accompanied by leptin deficiency. Sainz 
et al. demonstrated in ob/ob mice that thiobarbi-
turic acid reactive substances (and therefore lip-
id peroxidation status) and the normalization of 
glycemia and insulinemia followed leptin admin-
istration [44]. Moreover, Sainz et al. also reported 
that leptin administration altered the expression 
of 1276 genes, including 86 involved in oxidative 
stress, immunological, and inflammatory process-
es [44]. This would therefore suggest that leptin 
plays multiple roles in glycemic homeostasis. 
Recently, the problem of abnormal weight has 
been highlighted in patients with T1DM, i.e. the 
results of anthropometric studies of ~33,000 pe-
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diatric patients with T1DM from western Europe 
and the USA showed that ~ 40% of the population 
studied presented abnormalities in the body com-
position, and a significant, positive correlation be-
tween BMI z-score and HbA1c [%] was found in the 
6–17 age group [45]. The co-occurrence of type 1 
and type 2 diabetes (with insulin resistance) and 
MODY (maturity onset diabetes of the young) type 
diabetes mellitus in a  pediatric patient [46] and 
in particular, the co-occurrence of MODY-type dia-
betes specific biomarkers and T1DM-specific anti-
gens were also previously observed [47, 48]. Such 
cases represent significant diagnostic and thera-
peutic challenges, and therefore, in the treatment 
of quantitative and qualitative malnutrition, at-
tention should be paid to not increase the mass of 
adipose tissue excessively in patients with T1DM, 
due to the risk of developing insulin resistance.
In this study HbA1c was significantly lower in 
the population treated with an insulin pump than 
in the patients treated with insulin pens. Similar 
results have been reported previously in a  study 
by Olsen et al. [49]. Based on the recent defini-
tions of metabolic control in T1DM introduced by 
the International Society for Pediatric and Adoles-
cents Diabetes (ISPAD) [50] and the American Di-
abetes Association (ADA), a correct level of HbA1c 
(so less than or equal to 7.5%; 58 mmol/mol) [51] 
was observed in most of our patients treated with 
an insulin pump, but less than 50% of patients 
treated with insulin pens. The T1DM pump group, 
but not the T1DM pen group, exhibited compara-
ble levels of NPW as the control group. It could be 
speculated that the levels of insulin and glucose, 
in a  similar fashion to NPW level, are more nor-
malized in the T1DM pump group as compared to 
the T1DM pen group. The indirect proof is relat-
ed to the association between lower HbA1c in the 
T1DM pump group than T1DM pen group and the 
positive correlation between NPW and TAS in the 
T1DM pen group. The administration of an insu-
lin analogue in the pump consists of a continuous 
subcutaneous infusion of the hormone that mim-
ics the constant secretion of insulin in the pan-
creas. HbA1c is a  good parameter evaluating the 
results of diabetic treatment, but quite “broad”, 
because it shows only the average glycemia value 
from the last 3 months and does not reflect glyce-
mic fluctuation. This means that there can be the 
same HbA1c value in a patient who has large blood 
glucose fluctuations at this time and in a patient 
with small fluctuations, as long as the mean glyce-
mia is the same. T1DM patients using insulin pens 
have larger glycemic fluctuations because of the 
hypoinsulinemia period than in the T1DM pump 
population. In the latter case, if insulin pumps are 
properly used, the blood glucose fluctuations are 
leveled out, and therefore low HbA1c values can be 
achieved, close to the reference values, without 
exposing the patient to severe hypoglycemia [50]. 
The above difference can be significant in the as-
pect of the impact of various tissues on glycemic 
metabolism.
Our study has some limitations. The analysis 
used body mass and height measurements to de-
termine the anthropometric indices (BMI z-score, 
Cole index, and BMI-for-age percentile) recom-
mended for the assessment of nutritional status 
in children and adolescents. More advanced an-
thropometric analyses, such as electric bioimped-
ance, would allow for the accurate evaluation of 
lean tissue but are not available for children [52]. 
It is worth considering expanding biochemical 
analyses to larger research groups, which in the 
case of pediatric patients is not easy to arrange. 
The next limitation is that in the T1DM pen group 
we included patients who used human insulin 
and/or analog insulin. The patients with pumps 
used only rapid analog insulin, and thus it is worth 
performing a separate study with patients treated 
with pens using only analog insulin. Therefore, fu-
ture investigation is required.
In conclusion, nutritional indicators (the pro-
file of leptin and anthropometric parameters) 
and antioxidant status may play an essential role 
in shaping NPB and NPW in people with T1DM. 
Serum levels of NPW and NPB, adiponectin and 
especially of leptin could be considered in de-
tailed diagnostics of pediatric and adolescent pa-
tients with T1DM, primarily in populations with 
abnormal anthropometric indices, antioxidant 
status and those treated using insulin pens. The 
lack of correlation with HbA1c raises the suspi-
cion of a  lack of a  significant impact of the re-
sults of treatment (which is substitution, i.e. it is 
symptomatic) on energy and nutritional process-
es, which more clearly depend on other factors: 
CNS function, endocrine homeostasis, and genes 
(gender). The effects of gender and the form of 
insulin treatment on the relationship between 
NPB and leptin and antioxidant status in T1DM 
require however further investigation. 
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